Related Experiment Video
Updated: Apr 21, 2026
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
Down-regulation of survivin alleviates experimental arthritis
K M E Andersson1, M N D Svensson1, M C Erlandsson1
1Department of Rheumatology and Inflammation Research, Sahlgrenska University Hospital, University of Gothenburg, Sweden.
Abstract:
Survivin is a proto-oncogene that regulates cell division and apoptosis. It is a molecular marker of cancer. Recently, survivin has emerged as a feature of RA, associated with severe joint damage and poor treatment response. The present study examined if inhibition of survivin affects experimental arthritis, which was induced in mBSA-immunized mice by an injection of mBSA in the knee joint or developed spontaneously in collagen type II-immunized mice. The inhibition of survivin transcription by a lentivirus shRNA construct alleviated joint inflammation and reduced bone damage. The inhibition of survivin reduced the levels of metalloproteinases, β-catenin, and vimentin, limiting the invasive capacity of synovia, while no inhibition of osteoclastogenesis could be found. The inhibition of survivin led to a p53-independent reduction of T cell proliferation and favored the transcription and activity of Blimp-1, which limited IL-2 production and facilitated formation of regulatory Foxp3(+)CD4(+) and effector CD8(+) T cells. The study shows that the inhibition of survivin is sufficient to reduce joint inflammation and bone damage in preclinical models of arthritis. Antiarthritic effects of survivin inhibition are related to p53-independent control of lymphocyte proliferation.
Insights
Inhibiting survivin, a cancer-related gene, reduced joint inflammation and bone damage in preclinical arthritis models. This targeted approach impacts T cell proliferation and immune responses, offering new therapeutic avenues for rheumatoid arthritis.
Area of Science:
- Immunology
- Molecular Biology
- Rheumatology
Background:
- Survivin is a proto-oncogene and cancer marker linked to severe joint damage in rheumatoid arthritis (RA).
- Its role in RA pathogenesis and potential as a therapeutic target remain under investigation.
Purpose of the Study:
- To investigate the therapeutic potential of survivin inhibition in experimental arthritis models.
- To elucidate the molecular mechanisms underlying survivin's role in arthritis.
Main Methods:
- Experimental arthritis was induced in mice using mBSA and collagen type II immunization.
- Survivin transcription was inhibited using lentivirus shRNA constructs.
- Levels of metalloproteinases, β-catenin, vimentin, and T cell populations were analyzed.
Main Results:
- Survivin inhibition alleviated joint inflammation and reduced bone damage in preclinical arthritis models.
- Inhibition decreased metalloproteinases, β-catenin, and vimentin, limiting synovial invasiveness.
- Survivin inhibition reduced T cell proliferation independently of p53, promoting regulatory and effector T cell formation.
Conclusions:
- Survivin inhibition demonstrates significant antiarthritic effects in preclinical models.
- Targeting survivin impacts lymphocyte proliferation and immune cell balance, suggesting a novel therapeutic strategy for RA.
